Hetrombopag
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Hetrombopag
- DrugBank Accession Number
- DB16184
- Background
Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 458.474
Monoisotopic: 458.159019824 - Chemical Formula
- C25H22N4O5
- Synonyms
- Not Available
- External IDs
- SHR-8735
- SHR8735
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9WGT51BDDL
- CAS number
- 1257792-41-8
- InChI Key
- BDGGFTDRPHKXFC-QYQHSDTDSA-N
- InChI
- InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,26,30H,2-3,5-6H2,1H3,(H,32,33)/b27-22-
- IUPAC Name
- 5-(2-hydroxy-3-{2-[(4Z)-3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-4,5-dihydro-1H-pyrazol-4-ylidene]hydrazin-1-yl}phenyl)furan-2-carboxylic acid
- SMILES
- CC1=NN(C(=O)\C1=N/NC1=C(O)C(=CC=C1)C1=CC=C(O1)C(O)=O)C1=CC=C2CCCCC2=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 52084807
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Other Primary Immune Thrombocytopenia (ITP) 1 3 Active Not Recruiting Treatment Chemotherapy-Induced Thrombocytopenia 1 3 Not Yet Recruiting Treatment Chemotherapy-Induced Thrombocytopenia 1 3 Recruiting Treatment Immune Thrombocytopenia (ITP) 1 3 Withdrawn Treatment Chemotherapy-Induced Thrombocytopenia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0528 mg/mL ALOGPS logP 4.03 ALOGPS logP 5.43 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 3.13 Chemaxon pKa (Strongest Basic) -0.35 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 127.73 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 126.15 m3·mol-1 Chemaxon Polarizability 49.15 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0010900000-1eefb384f396923baabd Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0bti-0010900000-792a872eada472716e3b Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0112900000-1e5172f7e9f69fabf4d0 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-03ei-0373900000-2afa4c6ddc34334f4f6d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-053i-2369700000-a8e535d56399f4727a9c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-015c-1659200000-9a7498c7f51362f15056 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 15, 2020 18:14 / Updated at December 20, 2020 03:38